RGC®

Regeneron Genetics Center

Regeneron Genetics Center (RGC) is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics. The primary goal of RGC is to improve patient outcomes by identifying novel drug targets, clinical indications for development programs, and genomic biomarkers for pharmacogenomic applications.

Therapeutic Areas of Interest



"RGC applies the best and latest technologies in sequencing and analytics to harness the power of human genetics to create game changing new medicines." – Aris Baras, Head of RGC

RGC Milestones

2013 Regeneron sought to further explore the human genetic code and RGC was born. Launched foundational initiative with Geisinger to sequence 100k participants.

2017 Discovered inhibition of ANGPTL3 gene in humans and mice is associated with decreased levels of all 3 major lipid fractions and protection from atherosclerotic cardiovascular disease.

2018 Uncovered loss-of-function variant in HSD17B13 gene associated with reduced risk of chronic liver disease. Partnered with UK Biobank to accelerate our research goals.

2020 Sequenced our 1,000,000th exome – first organization in the world to do so.

2021 Discovered rare genetic mutations in GPR75 gene associated with protection against obesity.

2022 Uncovered a novel association between rare mutations in the CIDEB gene and protection from liver damage and disease.

2023 10-year anniversary of RGC's founding.

2024 Validated whole exome sequencing approach with peer-reviewed publication.

2025 Launched collaboration with Truveta to sequence up to 10 million de-identified patient volunteers. Initiated world's most comprehensive study of proteins with UK Biobank and biopharma partners.

Science-Led

World-class scientists & researchers.

250+
publications authored
based on RGC data

1st
organization
to sequence 1 million exomes

RGC Collaborations

Global network of collaborator institutions.

150+
collaborations

~ 30
countries

The Database

Largest & most diverse in the world.

~ 3M
exomes sequenced and counting

700K+
underrepresented individuals sequenced

Development of Therapeutics

Our mission: genetics to therapeutics, designed for all.

12
genetics medicines programs in the clinic

~ 40
therapeutic programs started from novel RGC targets or known genes with novel RGC insights

25+
novel genetic targets discovered

50+
novel protective genetics discoveries

Science Obsessed, Human Inspired.